Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631583 | 0.92 | TSHR (0.43) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL1305572 | 0.91 | TSHR (0.46) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL7450340 | 0.89 | MAPT (0.48) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL24462561 | 0.88 | PPARD (0.42) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL13631717 | 0.88 | TSHR (0.40) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL5002524 | 0.87 | TSHR (0.39) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL13805269 | 0.87 | TSHR (0.39) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL13631390 | 0.87 | TSHR (0.39) | TSHRPPARDKDM4EALDH1A1POLB | |
| SCHEMBL11032582 | 0.86 | TSHR (0.50) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL7505873 | 0.86 | TSHR (0.41) | TSHRPPARDKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2020102820-A1 | COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | SLC40A1, TAC3, ABCB7 | TSHR 463/4885PPARD 4086/4885KDM4E 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.